TransCode Therapeutics (NASDAQ: RNAZ) presented clinical data from its Phase 1a trial of TTX-MC138 at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The results, shared in poster 1025P, showed that the investigational therapy met its primary safety endpoint with no dose-limiting toxicities across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. The news matters because it marks the first clinical safety readout for a drug designed to target microRNA-10b, a biomarker associated with metastasis, and it opens the door for continued evaluation in patients with advanced solid tumors.
The ongoing multicenter, open-label study is evaluating safety, tolerability, pharmacokinetics, antitumor activity, and exploratory biomarkers in patients with previously treated advanced solid tumors. TTX-MC138 was administered once every 28 days, and researchers observed dose-dependent plasma exposure across all evaluated doses. The absence of dose-limiting toxicities is a critical milestone for any oncology candidate, as it suggests the drug may be safely combined or escalated in future trials. Moreover, the company reported disease stabilization and extended progression-free intervals in a subset of patients, providing early signals of clinical benefit that warrant further investigation.
For TransCode Therapeutics, a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, these findings could bolster its position in the competitive oncology landscape. The lead candidate TTX-MC138 targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. If subsequent trials confirm the safety and preliminary efficacy seen in Phase 1a, the drug could address a significant unmet need for patients with advanced cancers that have limited treatment options.
The data were released through InvestorWire, a specialized communications platform that distributes press releases for public companies. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers services including editorial syndication to 5,000+ outlets and social media distribution. The full press release can be viewed at https://ibn.fm/g3E2F. For ongoing updates on TransCode Therapeutics (NASDAQ: RNAZ), the company’s newsroom is available at https://ibn.fm/RNAZ.
The implications of this announcement extend beyond the immediate safety data. A clean safety profile in Phase 1a is often a prerequisite for advancing to Phase 1b/2 trials, where efficacy becomes the primary focus. For investors, the results reduce some of the regulatory and clinical risks associated with early-stage drug development. For the scientific community, the confirmation that an RNA-targeting agent can be administered safely in humans adds to the growing body of evidence supporting RNA-based therapeutics in oncology. As TransCode continues to enroll patients and gather longer-term follow-up, the focus will shift to whether the disease stabilization observed in some patients translates into meaningful survival benefits in larger, controlled studies.
